<mods xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" version="3.3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" ID="P0b002ee18039db03">
<name type="corporate">
 <namePart>United States Government Publishing Office</namePart>
 <role>
  <roleTerm authority="marcrelator" type="text">publisher</roleTerm>
  <roleTerm authority="marcrelator" type="code">pbl</roleTerm>
</role>
 <role>
  <roleTerm authority="marcrelator" type="text">distributor</roleTerm>
  <roleTerm authority="marcrelator" type="code">dst</roleTerm>
</role>
</name>
<name type="corporate">
 <namePart>United States</namePart>
 <namePart>Government Accountability Office</namePart>
 <namePart>Health, Education, and Human Services Division</namePart>
 <role>
  <roleTerm authority="marcrelator" type="text">author</roleTerm>
  <roleTerm authority="marcrelator" type="code">aut</roleTerm>
</role>
 <description>Government Organization</description>
</name>
<typeOfResource>text</typeOfResource>
<genre authority="marcgt">government publication</genre>
<language>
 <languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<extension>
 <collectionCode>GAOREPORTS</collectionCode>
 <category>Legislative Agency Publications</category>
 <waisDatabaseName>gao</waisDatabaseName>
 <branch>legislative</branch>
 <dateIngested>2010-08-12</dateIngested>
</extension>
<originInfo>
 <publisher>U.S. Government Printing Office</publisher>
 <dateIssued encoding="w3cdtf">1995-11-09</dateIssued>
 <issuance>monographic</issuance>
</originInfo>
<physicalDescription>
 <note type="source content type">deposited</note>
 <digitalOrigin>born digital</digitalOrigin>
 <extent>34 p.</extent>
</physicalDescription>
<classification authority="sudocs">GA 1.13:HEHS-96-45</classification>
<identifier type="uri">https://www.govinfo.gov/app/details/GAOREPORTS-HEHS-96-45</identifier>
<identifier type="local">P0b002ee18039db03</identifier>
<identifier type="former package identifier">f:he96045</identifier>
<recordInfo>
 <recordContentSource authority="marcorg">DGPO</recordContentSource>
 <recordCreationDate encoding="w3cdtf">2010-08-12</recordCreationDate>
 <recordChangeDate encoding="w3cdtf">2011-03-24</recordChangeDate>
 <recordIdentifier source="DGPO">GAOREPORTS-HEHS-96-45</recordIdentifier>
 <recordOrigin>machine generated</recordOrigin>
 <languageOfCataloging>
  <languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</languageOfCataloging>
</recordInfo>
<accessCondition type="GPO scope determination">fdlp</accessCondition>
<extension>
 <docClass>REPORT</docClass>
 <accessId>GAOREPORTS-HEHS-96-45</accessId>
 <reportNumber>HEHS-96-45</reportNumber>
 <subject>Pharmaceutical industry</subject>
 <subject>Competition limitation</subject>
 <subject>Cost control</subject>
 <subject>Drugs</subject>
 <subject>Unfair competition</subject>
 <subject>Monitoring</subject>
 <subject>Employee medical benefits</subject>
 <subject>Health insurance</subject>
 <subject>Sales promotion</subject>
 <subject>Cost effectiveness analysis</subject>
 <type>Letter Report</type>
 <seriesAbbrev>HEHS</seriesAbbrev>
</extension>
<titleInfo>
 <title>Pharmacy Benefit Managers: Early Results on Ventures with Drug Manufacturers</title>
</titleInfo>
<abstract>Pursuant to a congressional request, GAO reviewed mergers between
pharmacy benefit managers (PBM) and pharmaceutical manufacturers,
focusing on: (1) PBM role in the health care industry; (2) the mergers&apos;
objectives and effect on competition; and (3) the extent to which PBM
have given preference to their manufacturer partners&apos; drugs.&lt;p/&gt;GAO found that: (1) drug manufacturers have allied with PBM to help
maintain their profits in an increasingly competitive marketplace; (2)
PBM help health plan sponsors administer prescription drug benefits and
help them contain their overall drug costs; (3) manufacturers rely on
their PBM partners to help them develop new programs for treating
specific diseases and increase the market share for their drugs; (4)
critics of PBM alliances are concerned that the companies involved could
act to restrict competition among manufacturers for inclusion on PBM
formularies; (5) variations exist in the extent to which PBM have given
preferences to their manufacturer partners&apos; drugs; and (6) the Federal
Trade Commission monitors PBM alliances to help ensure that PBM maintain
competitive processes that allow other manufacturers to compete for
low-cost designation for their drugs on PBM formularies.</abstract>
<location>
 <url displayLabel="HTML rendition" access="raw object">https://www.govinfo.gov/content/pkg/GAOREPORTS-HEHS-96-45/html/GAOREPORTS-HEHS-96-45.htm</url>
 <url displayLabel="PDF rendition" access="raw object">https://www.govinfo.gov/content/pkg/GAOREPORTS-HEHS-96-45/pdf/GAOREPORTS-HEHS-96-45.pdf</url>
</location>
<identifier type="preferred citation">GAO/HEHS-96-45</identifier>
<location>
 <url displayLabel="Content Detail" access="object in context">https://www.govinfo.gov/app/details/GAOREPORTS-HEHS-96-45</url>
</location>
<note>Letter Report</note>
<extension>
 <searchTitle>GAO/HEHS-96-45; Pharmacy Benefit Managers: Early Results on Ventures with Drug Manufacturers;
            </searchTitle>
</extension>
<subject>
 <topic>Pharmaceutical industry</topic>
 <topic>Competition limitation</topic>
 <topic>Cost control</topic>
 <topic>Drugs</topic>
 <topic>Unfair competition</topic>
 <topic>Monitoring</topic>
 <topic>Employee medical benefits</topic>
 <topic>Health insurance</topic>
 <topic>Sales promotion</topic>
 <topic>Cost effectiveness analysis</topic>
</subject>
</mods>